Platinum

Where the papers sit

14 papers from the last 6 months study platinum directly · updated from PubMed 26 Oct 2026

• Platinum Chemotherapy Outcomes

  Platinum chemotherapy is being evaluated less as a uniform regimen than through survival, toxicity, and molecular context. BRCA1/2 status, platinum-adduct mutational signatures, and oxaliplatin-associated oxidative stress recur as markers of response or harm. In advanced NSCLC, durvalumab–etoposide-platinum and thoracic radiotherapy represent combination strategies, while studies also examine liver aging and new platinum nanostructures. The evidence supports patient selection and safer combinations more clearly than one superior regimen.

  7 papers · 50%

• Metal-Based Cancer Therapy

  Metal-based cancer treatment is moving toward rationally designed compounds paired with delivery systems and treatment-context optimization. Cisplatin and related metallodrugs are being modeled computationally, while CuO nanoparticles and inhalable nitric oxide nanogenerators aim to improve localization or add immune activation. Pancreatic cancer work emphasizes protocol adherence during neoadjuvant treatment rather than a new agent. Together, the cluster favors targeted, multifunctional therapy, but clinical benefit remains less established than chemical design and cytotoxicity.

  4 papers · 28.6%

• Targeted Platinum Cancer Therapy

  Catalytic, tumor-targeted platinum agents are being developed alongside strategies to reverse acquired platinum resistance. CDK12/13 inhibition overcomes resistance by disrupting RNA metabolism and alternative mRNA splicing through the spliceosome. Platinum(IV) metallo-stapled prodrugs aim to combine chemotherapy with immunometabolic effects, while platinum nanozymes seek high-efficiency catalytic therapy. The shared direction is more selective combination treatment rather than platinum monotherapy, but efficacy and tumor selectivity remain open.

  3 papers · 21.4%